Company Encyclopedia
View More
name
Charles River Laboratorie
CRL.US
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.
770.89 B
CRL.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Life Sciences Tools and ServicesIndustry
Industry Ranking44/60
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-2.32%D
    • Profit Margin-2.04%D
    • Gross Margin35.04%C
  • Growth ScoreD
    • Revenue YoY-0.92%D
    • Net Profit YoY-120.21%E
    • Total Assets YoY-6.12%D
    • Net Assets YoY-9.85%D
  • Cash ScoreD
    • Cash Flow Margin-4819.85%E
    • OCF YoY-0.92%D
  • Operating ScoreC
    • Turnover0.52C
  • Debt ScoreC
    • Gearing Ratio54.07%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    New York State Common Retirement Fund Reduces Position in Charles River Laboratories International, Inc. $CRL

    New York State Common Retirement Fund reduced its stake in Charles River Laboratories International by 15.8% in Q2, owning 111,008 shares worth $16.8 million. Other institutional investors adjusted their positions as well. Analysts have varied ratings on CRL, with some upgrading to 'strong-buy' and others adjusting price targets. The company reported Q3 earnings of $2.43 per share, beating estimates, with revenue slightly down year-over-year.

    Market Beat·
    US
    CRL
    -0.34%
    Market Beat·
    US
    CRL
    -0.34%

    Charles River Laboratories Presents at Evercore 8th Annual Healthcare Conference

    Charles River Laboratories presented at the Evercore 8th Annual Healthcare Conference, discussing fourth-quarter demand trends and improvements in Discovery and Safety Assessment booking activity. The company noted positive momentum in DSA net book-to-bill since Q3 2025, while acknowledging potential impacts from holiday seasonality on near-term proposals and bookings.

    Reuters·
    US
    CRL
    -0.34%
    Reuters·
    US
    CRL
    -0.34%

    Charles River Laboratories International Inc. Stock Underperforms Monday When Compared To Competitors

    Charles River Laboratories International Inc. (CRL) shares fell 1.15% to $176.09 on Monday, underperforming compared to some competitors. The S&P 500 Index and Dow Jones Industrial Average also declined. CRL is 13.26% below its 52-week high of $203.01. Competitors showed mixed results: Labcorp Holdings Inc. fell 0.39%, Alnylam Pharmaceuticals Inc. rose 0.74%, and Bio-Techne Corp. fell 1.16%. Data compiled on December 1, 2025.

    Dow Jones·
    US
    CRL
    -0.34%
    Dow Jones·
    US
    CRL
    -0.34%

    15:42 ET HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

    Halper Sadeh LLC, an investor rights law firm, is investigating potential breaches of fiduciary duties by officers and directors of Charles River Laboratories International, Inc. Shareholders are encouraged to contact the firm to discuss their rights, as they may seek corporate governance reforms or other relief. The firm handles cases on a contingent fee basis, aiming to improve company policies and enhance shareholder value.

    prnewswire·
    US
    CRL
    -0.34%
    prnewswire·
    US
    CRL
    -0.34%

    Charles River Laboratories to Present at Evercore Healthcare Conference

    Charles River Laboratories will present at the Evercore 8th Annual Healthcare Conference on December 3rd, discussing strategic focus, business developments, and trends. A live webcast will be available on their Investor Relations website, with a replay accessible for two weeks. The news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    CRL
    -0.34%
    Reuters·
    US
    CRL
    -0.34%
    © 2025 Longbridge｜Disclaimer